title: Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
abstract: Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.
authors.affiliation: Dept. of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. jpoelen@hotmail.com
authors.forename: Janneke
authors.initials: J
authors.lastname: Poelen
authors.forename: Mathé J J
authors.initials: MJ
authors.lastname: Prick
authors.forename: Judith W M
authors.initials: JW
authors.lastname: Jeuken
authors.forename: Pieter
authors.initials: P
authors.lastname: Wesseling
authors.forename: Hans J J A
authors.initials: HJ
authors.lastname: Bernsen
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D017741:Survivors; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide